March - 2013
| Previous Next | Showing Journal 2 of 13 |
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis - The ACCESS Randomized Trialthe ACCESS Study Group JAMA, 2013, 309(11):1154-1162 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
March |
Previous Comments
| I guess to do it in sepsis within 12 hours, you're not going to know if they have gram negative sepsis until its too late... | |
| Con-23 Mar, 2013 12:54:13 PM | |
Comment
This randomised RCT examines the effect of Eritoran in patients with sepsis.If, like me, you dont know anything about Eritoran, it is a synthetic lipid A antagonist that blocks LPS binding at the cell surface MD2-TLR4 receptor. As LPS is a big factor in gram negative bacteria activity and...